Lantern Pharma Inc (LTRN) 뉴스

Lantern Pharma Expands AI Capabilities of RADR® Platform to Accelerate the Clinical Development of Immune Checkpoint Inhibitors

Expansion of RADR® platform adds new AI capabilities for the automated identification of new and effective combination therapy regimens for...

Lantern Pharma Receives Notice of US Patent Allowance for Drug Candidate LP-184 for the Treatment of Rare Pediatric Brain Cancer, ATRT

LP-184 is the first of Lantern’s drug candidates developed by leveraging Lantern’s AI platform, RADR® US FDA previously granted LP-184 Rare...

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Form 8-K - Current report

Lantern Pharma Reports Second Quarter 2023 Financial Results and Operational Highlights

Obtained FDA clearance of the IND application for LP-184 and activated initial clinical sites for the Phase 1 basket trial in...

Lantern Pharma to Report Second Quarter 2023 Operating & Financial Results on August 9, 2023 at 4:30 p.m. ET

Webcast to be held Wednesday, August 9, 4:30 p.m. ET, register here, or at the link below. Lantern Pharma Inc. (NASDAQ: LTRN), an artificial...

Lantern Pharma to Participate and Present at Multiple Upcoming Conferences

Lantern Pharma Inc. (NASDAQ: LTRN), an artificial intelligence (“AI”) company developing targeted and transformative cancer therapies using its...

Oncotarget Publishes New Data by Lantern Pharma, an AI Company Developing Cancer Therapies, Further Supporting Clinical Advancement of LP-284, a Novel Synthetically Lethal Drug Candidate for Non-Hodgkin’s Lymphomas

Non-Hodgkin’s lymphoma (NHL) is the seventh leading cause of cancer in the US, with 20-40% of patients...

Lantern Pharma Receives FDA Clearance of IND Application for Drug Candidate LP-184 in Solid Tumors

LP-184 is a novel, synthetically-lethal, small molecule that has been developed using insights from Lantern’s AI platform, RADR®. The...

Lantern Pharma Leverages AI Platform, RADR®, to Develop Breakthrough Antibody Drug Conjugates (ADCs) in Collaboration with Bielefeld University

Lantern will leverage its proprietary AI platform, RADR®, to rapidly develop novel cryptophycin-antibody drug...

Lantern Pharma to Present at the Lytham Partners Spring 2023 Investor Conference Thursday, May 18th at 9:00 a.m. ET

Lantern Pharma Inc. (NASDAQ: LTRN), a clinical-stage biopharmaceutical company using its proprietary RADR® artificial intelligence ("AI") and...

Lantern Pharma Reports First Quarter 2023 Financial Results and Operational Highlights

Dosed first patient in the Phase 2 Harmonic™ clinical trial; a study for the unique population of non-small lung cancer patients who are...

Annual Report to Security Holders (ars)

Lantern Pharma Selects REPROCELL USA to Provide Support for the Phase 2 Harmonic™ Clinical Trial

Lantern Pharma Selects REPROCELL USA to Provide Support for the Phase 2 Harmonic™ Clinical Trial PR...

Lantern Pharma to Report First Quarter 2023 Operating & Financial Results on May 9, 2023 at 4:30 p.m. ET

Webcast to be held Tuesday, May 9, 4:30 p.m. ET, register here, or at the link below. Lantern Pharma Inc. (NASDAQ: LTRN), a clinical-stage...